BioMEMS and Biomedical Nanotechnology [electronic resource] : Volume III Therapeutic Micro/Nanotechnology / edited by Mauro Ferrari, Tejal Desai, Sangeeta Bhatia.Material type: TextLanguage: English Publisher: Boston, MA : Springer US, 2007Description: XXIV, 376 p. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9780387258447Subject(s): Engineering | Medicine | Biotechnology | Biomedical engineering | Nanotechnology | Engineering | Biomedical Engineering | Biophysics and Biological Physics | Nanotechnology | Biomedicine general | BiotechnologyAdditional physical formats: Printed edition:: No titleDDC classification: 610.28 LOC classification: R856-857Online resources: Click here to access online
Cell-based Therapeutics -- Nano- and Micro-Technology to Spatially and Temporally Control Proteins for Neural Regeneration -- 3-D Fabrication Technology for Tissue Engineering -- Designed Self-assembling Peptide Nanobiomaterials -- At the Interface: Advanced Microfluidic Assays for Study of Cell Function -- Multi-phenotypic Cellular Arrays for Biosensing -- Mems and Neurosurgery -- Drug Delivery -- Vascular Zip Codes and Nanoparticle Targeting -- Engineering Biocompatible Quantum Dots for Ultrasensitive, Real-Time Biological Imaging and Detection -- Diagnostic and Therapeutic Applications of Metal Nanoshells -- Nanoporous Microsystems for Islet Cell Replacement -- Medical Nanotechnology and Pulmonary Pathology -- Nanodesigned Pore-Containing Systems for Biosensing and Controlled Drug Release -- Transdermal Drug Delivery using Low-Frequency Sonophoresis -- Microdevices for Oral Drug Delivery -- Nanoporous Implants for Controlled Drug Delivery -- Molecular Surface Engineering for the Biological Interface -- Micro and Nanoscale Smart Polymer Technologies in Biomedicine -- Supported Lipid Bilayers as Mimics for Cell Surfaces and as Tools in Biotechnology -- Engineering Cell Adhesion -- Cell Biology on a Chip: A Microfluidic Cell Culture Laboratory.
Less than twenty years ago photolithography and medicine were total strangers to one another. They had not yet met, and not even looking each other up in the classi?eds. And then, nucleic acid chips, micro?uidics and microarrays entered the scene, and rapidly these strangers became indispensable partners in biomedicine. Asrecentlyastenyearsagothenotionofapplyingnanotechnologytothe?ghtagainstd- ease was dominantly the province of the ?ction writers. Thoughts of nanoparticle-vehicled deliveryoftherapeuticalstodiseasedsiteswereanexerciseinscienti?csolitude,andgrounds for questioning one’s ability to think “like an established scientist”. And today we have nanoparticulate paclitaxel as the prime option against metastatic breast cancer, proteomic pro?lingdiagnostictoolsbasedontargetsurfacenanotexturing,nanoparticlecontrastagents for all radiological modalities, nanotechnologies embedded in high-distribution laboratory equipment, and no less than 152 novel nanomedical entities in the regulatory pipeline in the US alone. Thisisatransformingimpact,byanymeasure,withclearevidenceoffurtheracceleration, supported by very vigorous investments by the public and private sectors throughout the world. Even joining the dots in a most conservative, linear fashion, it is easy to envision scenarios of personalized medicine such as the following: patient-speci?c prevention supplanting gross, faceless intervention strategies; early detection protocols identifying signs of developing disease at the time when the disease is most easily subdued; personally tailored intervention strategies that are so routinely and inexpensively realized, that access to them can be secured by everyone; technologies allowing for long lives in the company of disease, as good neighbors, without impairment of the quality of life itself.